Immunome (id:5733 IMNM)
9.82 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 12:40:10 PM)
Exchange closed, opens in 1 day 20 hours
3.81 USD (3.81%)
-3.44 USD (-3.44%)
-19.18 USD (-19.18%)
-32.04 USD (-32.04%)
22.90 USD (22.90%)
-37.29 USD (-37.29%)
About Immunome
Market Capitalization 618.24M
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
| Headquarters (address) |
18702 N. Creek Parkway Bothell 98011 WA United States |
| Phone | 610 321 3700 |
| Website | https://immunome.com |
| Employees | 78 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IMNM |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 6.93 - 30.96 |
| Market Capitalization | 618.24M |
| P/E trailing | -1.83 |
| P/E forward | -3.42 |
| Price/Sale | 61.04 |
| Price/Book | 1.99 |
| Beta | 1.82 |
| EPS | -7.54 |
| EPS United States (ID:6, base:3399) | 24.27 |